Interní Med. 2010; 12(9): 454-457
Metformin in combination with other antidiabetics
- Interní klinika FN Motol a 2. LF UK, Praha
Metformin is an ideal peroral antidiabetic drug for combining with all hypoglycemic drugs – peroral antidiabetics, incretin-based drugs,
as well as with insuline. Very favorable effects of metformin in combination are confirmed also by five available fixed metformin combinations
with other peroral antidiabetics in one tablet.
Keywords: metformin, combinational therapy
Published: October 1, 2010 Show citation
References
- Green BD, Irwin N, Duffy NA, et al. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006; 10, 547(1-3): 192-199.
Go to original source... 
Go to PubMed... - Bosi E. Metformin - the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab. 2009; 11(Suppl. 2): 3-8. Go to original source... Go to PubMed...
- Unger J, Parkin CG. Type 2 diabetes: an expanded view of pathophysiology and therapy. Postgrad Med. 2010; 122(3): 145-157. Go to original source... Go to PubMed...
- Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 810-816. Go to original source... Go to PubMed...
- Riedl AA, Heien H, Wogen J, et al. Loss of glycemic control on patients with type 2 diabetes mellitus who were receiving initial metformin, sulphonylurea, or thiazolidindione monotherapy. Pharmacotherapy 2007; 27(8): 1102-1110. Go to original source... Go to PubMed...
- Forst T, Weber MM, Löbig M, et al. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with type 2 diabetes mellitus. Clin Sci (Lond). 2010 May 28. [Epub ahead of print]. Go to original source... Go to PubMed...
- Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab. 2004; 17(6): 336-342.
- Green BD, Irwin N, Duffy NA, et al. Inhibition of dipeptidyl peptidase - IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006; 10, 547(1-3): 192-199. Go to original source... Go to PubMed...
- Williams-Herman D, Johnson J, Teng R. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010; 12(5): 442-451. Go to original source... Go to PubMed...
- Sharma MD. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag. 2010; 25(6): 233-237. Go to original source... Go to PubMed...
- Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med. 2005; 22(5): 654-657. Go to original source... Go to PubMed...
- Hermansen K, Kolotkin RL, Hammer M, et al. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Prim Care Diabetes. 2010 May 3. [Epub ahead of print]. Go to original source... Go to PubMed...
- Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 14, 303(14): 1410-1418. Go to original source... Go to PubMed...
- Kuritzky L, Epstein BJ, Lavernia F. How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation. Postgrad Med. 2010; 122(3): 33-42. Go to original source... Go to PubMed...